Tandem Diabetes Care (NASDAQ:TNDM) Raised to “Neutral” at Bank of America

Tandem Diabetes Care (NASDAQ:TNDM) was upgraded by investment analysts at Bank of America from an “underperform” rating to a “neutral” rating in a research note issued to investors on Friday, MarketBeat Ratings reports. The brokerage currently has a $30.00 target price on the medical device company’s stock, up from their prior target price of $15.00. Bank of America‘s price target suggests a potential upside of 22.10% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. Truist Financial set a $24.00 price objective on shares of Tandem Diabetes Care and gave the company a “hold” rating in a research note on Thursday, December 18th. Sanford C. Bernstein restated a “market perform” rating and set a $25.00 price target (up previously from $18.00) on shares of Tandem Diabetes Care in a report on Friday, January 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tandem Diabetes Care in a research report on Wednesday, January 21st. TD Cowen began coverage on Tandem Diabetes Care in a research report on Tuesday, January 27th. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, Mizuho boosted their target price on Tandem Diabetes Care from $18.00 to $21.00 and gave the company a “neutral” rating in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $25.50.

Tandem Diabetes Care Stock Performance

NASDAQ:TNDM opened at $24.57 on Friday. The company has a debt-to-equity ratio of 2.33, a quick ratio of 1.90 and a current ratio of 2.44. Tandem Diabetes Care has a fifty-two week low of $9.98 and a fifty-two week high of $35.12. The firm has a market cap of $1.67 billion, a PE ratio of -8.00 and a beta of 1.68. The business has a 50 day moving average price of $20.91 and a 200-day moving average price of $17.02.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its earnings results on Thursday, February 19th. The medical device company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.04. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 70.01%. The company had revenue of $290.38 million for the quarter, compared to the consensus estimate of $277.14 million. During the same period in the previous year, the firm earned $0.01 earnings per share. The firm’s revenue for the quarter was up 15.1% on a year-over-year basis. Equities research analysts predict that Tandem Diabetes Care will post -1.68 earnings per share for the current year.

Hedge Funds Weigh In On Tandem Diabetes Care

Several large investors have recently made changes to their positions in TNDM. Corient Private Wealth LLC bought a new stake in shares of Tandem Diabetes Care in the 4th quarter worth approximately $346,000. Mercer Global Advisors Inc. ADV purchased a new position in Tandem Diabetes Care during the fourth quarter valued at $248,000. EP Wealth Advisors LLC bought a new stake in Tandem Diabetes Care in the fourth quarter worth $219,000. Wellington Management Group LLP purchased a new stake in shares of Tandem Diabetes Care in the fourth quarter worth $2,161,000. Finally, Man Group plc purchased a new stake in shares of Tandem Diabetes Care in the fourth quarter worth $281,000.

Key Stories Impacting Tandem Diabetes Care

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q4 beat on top- and bottom-line metrics — revenue of $290.4M (vs. consensus ~$277M), EPS loss narrower than expected and record quarterly sales and pump shipments; management highlighted margin expansion. Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance
• Positive Sentiment: Market reaction: shares surged intraday after the results and outlook, reflecting investor enthusiasm for the beat, margin momentum and sales growth. Tandem Diabetes Shares Rise 33% On Earnings Beat, Margin Expansion, Growth Outlook
• Positive Sentiment: Analyst upgrades/raise: BofA moved TNDM from Underperform to Neutral and raised its target to $30, and several analysts raised forecasts or price targets after the upbeat quarter. These upgrades support further upside momentum. B of A Securities upgrades Tandem Diabetes Care (TNDM)
• Neutral Sentiment: FY‑2026 revenue guidance (~$1.1B) was reiterated/issued and generally in line with consensus — provides visibility but isn’t a clear upside surprise. Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance
• Neutral Sentiment: New pay-as-you-go (subscription) model announced — could expand long-term addressable market and recurring revenue but timing and transition impact are unclear. Tandem stock rises on Q4 beats, new pay-as-you-go model
• Negative Sentiment: Analyst caution: UBS and other analysts maintained Hold ratings, flagging pay‑go transition uncertainty and competitive headwinds that could limit near-term upside — supporting more conservative views. Tandem Diabetes Care: Solid Q4 Beat Offset by PayGo Transition Uncertainty and Competitive Headwinds Supporting Hold Rating
• Negative Sentiment: Mixed price-target moves: some firms raised targets but others (e.g., Stifel’s $22 target) still imply limited near-term upside versus the current price, underscoring divergent analyst views. Tandem Diabetes price target raised by Stifel

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.